BUILD A LEGACY OF SUPERIOR HEART FAILURE OUTCOMES1*
How your patients live their lives depends on the LVAD you choose. HeartMate 3™ LVAD with Full MagLev™ Flow Technology delivers unprecedented† survival and safety outcomes as demonstrated in the MOMENTUM 3 Trial at 2 years.1* With the HeartMate 3 LVAD, you can go above and beyond to make a meaningful difference in patient lives.
The highest published 2-year survival rate and the lowest published stroke and thrombosis rates for continuous-flow LVADS1-5
The HeartMate 3 LVAD is now approved for both Destination Therapy and Bridge to Transplant in patients with advanced refractory left ventricular heart failure.
Read more about the Clinical Evidence for HeartMate 3 LVAD.
Building comprehensive heart failure management
The HeartMate 3™ LVAD is part of our heart failure management portfolio. Our vision is to transform the treatment of heart failure by designing technology that delivers excellent clinical outcomes and improves workflow and efficiency. Read more about the portfolio and our approach to heart failure management.